Kwality Pharma Q1 FY27 Results (NSE: KPL)
Signal: Margin expansion
The read
The key inflection is a fourth consecutive quarter of margin expansion: consolidated EBITDA margin reached 25.3%, up 340bps YoY and 50bps QoQ, while revenue grew 46% YoY to ₹16297.49 lakh; the raised FY27 targets now require sustaining this mix and cost trajectory.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹162.97 Cr | 46% | 3% |
| Net profit | ₹25.62 Cr | 119% | |
| EPS | ₹24.69 | 115% | |
| EBIT margin | 25.3% |
P&L walk
Consolidated revenue rose to ₹16297.49 lakh, +46% YoY and +3% QoQ, while EBITDA margin increased to 25.3% from 21.9% and 24.8%; PAT rose 119% YoY to ₹2562.23 lakh as operating profit and margin expanded.
Segments
The company reports a single pharmaceuticals segment; the standalone-consolidated PAT gap was immaterial, with the foreign subsidiary contributing a ₹0.45 lakh loss.
Key positives
- Consolidated revenue reached ₹16297.49 lakh, +46% YoY and +3% QoQ, accelerating from +35.3% YoY in Q4FY26.
- EBITDA margin expanded 340bps YoY to 25.3%, following expansion from 22% in Q1FY25 to 24% in Q3FY26 and 25% in Q4FY26.
- The filing supports operating leverage: EBITDA grew 13% YoY to ₹41 crore versus revenue growth of 46%, while employee benefits plus other expenses grew only about 2% YoY; margin expanded 340bps.
- PAT rose 119% YoY to ₹2562.23 lakh and EPS rose 115% to ₹24.69, indicating earnings growth translated into per-share growth.
- 13 BE studies were completed during the quarter and filings have been made in 15+ countries, while 15+ new product registrations were secured.
- Management raised FY27 guidance to revenue of 700+ crore, EBITDA of ₹189-196+ crore and PAT of 109+ crore.
Key concerns
- Gross margin expanded approximately 2380bps YoY to 46.3% because raw-material-related costs fell to 53.7% of revenue from 77.5%; the filing does not disclose whether this was input deflation, pricing or mix, so durability requires confirmation.
- The FY27 revenue guidance of 700+ crore implies at least 39% YoY growth and the EBITDA guidance requires 27-28%+ margin, above the current 25.3% level.
- Depreciation declined 5% YoY to ₹499.47 lakh despite the scheduled Hormone facility completion by November 2026; the filing provides no asset-base data to assess the future depreciation ramp.
Research and educational content only. Not investment advice.